• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

ResMed (RMD)

Equity
Sell: $222.20|Buy: $275.00|Change: 0.34 (0.13%)

Open 

$251.48

Previous close 

$252.86

Trade high 

$254.99

Volume 

1,047,417

Year high 

$277.67

Year low 

$180.265

Dividend yield 

0.97%

Market capitalisation 

$35.61 bn

P/E ratio 

24.24

ISIN 

US7611521078

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Share price

Dividends

PreviousLatest
Record date14/05/202620/08/2026
Ex-dividend date14/05/202620/08/2026
Payment date18/06/202624/09/2026
Amount$0.60$0.66

Performance 23/10/2026

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

Total return (%)
ResMed- 0.08
More...

Company profile

ResMed makes continuous positive airway pressure devices and the masks used to treat obstructive sleep apnea, a condition in which the airway repeatedly collapses during sleep. Devices make up about half of revenue, masks and accessories close to 40%, and residential care software the remainder. Growth depends on diagnosing more of the large untreated sleep apnea population and moving them onto therapy. The Americas contribute about two-thirds of device and mask revenue, with most of the rest from Europe, Japan, and Australia.

Sector 

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.